Skip to content

Instantly share code, notes, and snippets.

@drcjar

drcjar/wellcome_ipf_funding.ipynb

Created January 16, 2020 15:23
Show Gist options
  • Save drcjar/db658d6b48282e1afd0fde6d81369ff9 to your computer and use it in GitHub Desktop.
Save drcjar/db658d6b48282e1afd0fde6d81369ff9 to your computer and use it in GitHub Desktop.
Download ZIP
wellcome ipf funding
Display the source blob
Display the rendered blob
Raw
wellcome_ipf_funding.ipynb
{
"cells": [
{
"cell_type": "code",
"execution_count": 12,
"metadata": {},
"outputs": [],
"source": [
"import pandas as pd\n",
"import pprint\n",
"import matplotlib.pyplot as plt\n",
"import seaborn as sbn\n",
"%matplotlib inline\n"
]
},
{
"cell_type": "code",
"execution_count": 13,
"metadata": {},
"outputs": [],
"source": [
"df = pd.read_excel('wellcome-grants-awarded-2005-2018.xlsx')"
]
},
{
"cell_type": "code",
"execution_count": 14,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"('Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial '\n",
" 'lung disease and is associated with high mortality. IPF therapies are '\n",
" 'limited and there is a significant need to understand the mechanisms '\n",
" 'involved. Airway macrophages (AMs) are the most abundant immune-cell in the '\n",
" 'IPF lung. Recent work demonstrated that IPF-AMs are characterised by high '\n",
" 'expession of glucose transport molecules; however, whether AM-glycolytic '\n",
" 'programming contributes to the pathogenesis of lung fibrosis remains '\n",
" 'unknown. My preliminary data indicates that IPF-AMs have a unique metabolic '\n",
" 'phenotype, characterised by reduced succinate and elevated Irg1 expression, '\n",
" 'a negative regulator of the citric acid cycle via itaconic acid. I '\n",
" 'hypothesise that AM glycolytic reprogramming contributes to the pathogenesis '\n",
" 'of lung fibrosis and manipulation of AM metabolism via itaconic acid, can '\n",
" 'ameliorate the disease. First, I will determine AM metabolic signatures in '\n",
" 'the fibrotic lung by metabolic assays in IPF-AMs and murine models. Second, '\n",
" 'I will assess Irg1 and itaconic acid levels in patient BAL/lung biopsies. '\n",
" 'Additionally, I will utilize siRNA knockdown in IPF-AMs and in parallel, '\n",
" 'Irg1-/- mice. This work will provide proof of principle for development of '\n",
" 'therapies which correct AM-metabolic dysregulation during IPF, paving the '\n",
" 'way for future grant applications and clinical studies. ')\n",
"('The goal of this project is to dissect the mechanisms that control '\n",
" 'homeostatic imprinting of pulmonary macrophages since it is these same '\n",
" 'processes that must be reinstated to restore homeostasis when macrophages '\n",
" 'behave aberrantly, such as during IPF where their behaviour underlies '\n",
" 'disease pathogenesis. Specifically, I will focus on the role of TGFb using a '\n",
" 'combination of novel macrophage-specific constitutive and inducible Cre '\n",
" 'drivers and Tgfbr1fl/fl mice to assess the role of TGFbR1 signalling in the '\n",
" 'acquisition of the niche-specific functions of pulmonary macrophage subsets. '\n",
" 'Multi-photon imaging will be used to assess the impact of Tgfbr1 deficiency '\n",
" 'on macrophage-niche interactions in real time in situ, alongside '\n",
" 'gene-expression profiling and functional assays. I will use the '\n",
" 'bleomycin-induced model of fibrosis to assess the roles of macrophage '\n",
" 'subsets in the inflammatory, fibrotic and resolution phases of fibrosis. '\n",
" 'Single cell RNA-Seq analysis will provide a comprehensive and unbiased '\n",
" 'interrogation of the heterogeneity of pulmonary macrophages and how these '\n",
" 'change during distinct phases of disease. Finally, temporal deletion of '\n",
" 'Tgfbr1 in distinct macrophage subsets will establish if TGFb plays differing '\n",
" 'roles at distinct stages of disease in distinct anatomical compartments, as '\n",
" 'well as revealing subset-specific functions of macrophages during disease. ')\n",
"('Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung '\n",
" 'disease causing hypoxemia and fatal respiratory failure. Incomplete '\n",
" 'understanding of pathogenic mechanisms hinders the development of effective '\n",
" 'therapies. Sudden deterioration due to acute exacerbations (AE-IPF), often '\n",
" 'triggered by infection, lead to rapid deterioration in the patients '\n",
" 'condition, often proving fatal. Lung macrophages are long-lived, highly '\n",
" 'oxygen sensitive, cells implicated in IPF pathogenesis. Their phenoty pe '\n",
" 'dictates their function. In IPF, alveolar macrophages (AM) are predominantly '\n",
" 'alternatively-activated (AAM). As IPF progresses, hypoxia activates '\n",
" 'hypoxia-inducible factors (HIF), with HIF-2, rather than HIF-1, found mainly '\n",
" 'in AAM. HIF-2 deletion in neutrophils improves infection resolution, however '\n",
" 'the role of HIF-2 in macrophage function and bactericidal activity, '\n",
" 'particularly in IPF, remains unknown. I aim to determine the role of HIF-2 '\n",
" 'in macrophages in IPF using mouse models of fibrosis, as well as human '\n",
" 'macrophages from IPF sufferers. I will also investigate the effects of HIF-2 '\n",
" 'activation in macrophages on their metabolic function and their phenotype. '\n",
" 'In order to assess the role of macrophages in AE-IPF, I will investigate the '\n",
" 'phenotype plasticity, as well as the bactericidal capacity of AM from mice '\n",
" 'undergoing lung fibrosis models, as well as from human IPF patient samples.')\n",
"('Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic lung disease '\n",
" 'which in 2012 was the recorded cause of death for c.4000 people in '\n",
" 'England/Wales. Its incidence is increasing and it is not known why. It is '\n",
" 'more common in men, manual workers, and those living in industrial areas. It '\n",
" 'is known that asbestosis can easily be clinically mistaken for IPF. This '\n",
" 'matters because there are implications for disease prevention, patient '\n",
" 'eligibility for compensation, and access to drug treatments. My overall aim '\n",
" 'is to characterize and measure asbestos exposure as an occupational '\n",
" 'determinant of IPF; additionally, I will investigate host-exposure '\n",
" 'interactions mediated by candidate susceptibility polymorphisms (in '\n",
" 'particular MUC5B promoter polymorphism rs35705950). My primary research '\n",
" 'question is: Does a dose-response relationship exist for occupational '\n",
" 'asbestos exposure and IPF? My secondary research question is: Does the '\n",
" 'presence of asbestos exposure modify the association between idiopathic '\n",
" 'pulmonary fibrosis and rs35705950? I will address my research questions '\n",
" 'using a multi-centre hospital based IPF case-control study. I will use '\n",
" 'proportionate mortality ratios for mesothelioma to assign risk of asbestos '\n",
" 'exposure using job titles, and a validated job process based asbestos '\n",
" 'exposure assessment questionnaire.')\n",
"('This project addresses long-term debilitating lung diseases, in particular '\n",
" 'Idiopathic Pulmonary Fibrosis (IPF). The project builds on pioneering work '\n",
" 'carried out by the University of Southampton and University Hospital '\n",
" \"Southampton. Nikon Metrology's microfocus CT technology (designed and built \"\n",
" 'in Tring, UK) w;Jf be used to examine samples of human lung. Traditionally, '\n",
" 'very thin sections are sliced and examined under a microscope, looking for '\n",
" 'changes in the lung structure caused by disease. These sections provide only '\n",
" 'a very limited idea of how far disease has degraded the vitally important 3D '\n",
" 'structure of the lung. This pioneering work overcomes those limitations, '\n",
" 'producing a new and exciting diagnostic capability. The microfocus CT '\n",
" 'technology delivers digital scans with resolution that is hundreds of times '\n",
" 'more detailed than conventional medical CT. Results will be validated '\n",
" 'against lung samples of known diagnosis. Advanced digital analysis allows '\n",
" 'the airways, blood vessels and areas for gas-exchange to be separately '\n",
" 'identified in 3D. This technique will ultimately enable the NHS to deliver '\n",
" 'earlier and more accurate diagnosis, improving patient outcomes and '\n",
" 'accurately target medication and surgery.')\n",
"('Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with '\n",
" 'significant unmet clinical needs. No therapy has been shown to improve a '\n",
" 'median survival of only 35 months. IPF is characterised by excessive '\n",
" 'proliferation of fibroblasts and their differentiation into myofibroblasts '\n",
" 'that produce large amounts of extracellular matrix (ECM) proteins including '\n",
" 'interstitial collagens. Although altered ECM cross-linking and stiffness at '\n",
" 'the cellular-scale are proposed to play a key role in t he mediation of IPF '\n",
" 'by promoting divergent myofibroblast behaviour, it is incompletely '\n",
" 'understood if, and at what scale, collagen assembly, accumulation, and '\n",
" 'biomechanical properties are altered in IPF. I hypothesise that aberrant '\n",
" 'collagen assembly and accumulation in IPF causes altered extracellular '\n",
" 'matrix physical properties and dynamics. This may promote the disease '\n",
" 'persistence and progression. Using cross-disciplinary collaboration, I '\n",
" 'propose to compare the ex vivo assembly and biome chanical properties of '\n",
" 'collagen in healthy and fibrotic lung tissue. I will then utilise a novel '\n",
" 'in vitro 3D primary human lung fibroblast culture model, and in vivo models, '\n",
" 'to examine the kinetics of collagen production and assembly in pulmonary '\n",
" 'fibrosis. Ultimately this work will increase understanding of ECM '\n",
" 'regulation in pulmonary fibrosis, and may aid in the identification of '\n",
" 'therapeutic targets.')\n",
"('VEGF is a potent cell mitogen and permeability factor that is produced in '\n",
" 'large quantities in the alveolar space. It has been suggested to have an '\n",
" 'important role in maintaining a healthy alveolar capillary membrane (ACM). '\n",
" 'Injury to the ACM may play a role in the development of pulmonary fibrosis '\n",
" '(IPF).This led me to the hypothesis that VEGF is a key regulator of '\n",
" 'fibroblast activity in the normal lung and that changes in bioavailability '\n",
" 'are involved in IPF development. The project is a natural ex tension to '\n",
" 'preliminary data showing that normal fibroblasts express receptors and '\n",
" 'co-factors of VEGF and produce several VEGF isoforms. In addition, VEGF165 '\n",
" 'induced proliferation of fibroblasts was inhibited by VEGF165b (a novel VEGF '\n",
" 'family that blocks several properties of VEGF). I propose to employ a '\n",
" 'translational approach to investigate the following: 1)To identify/quantify '\n",
" 'the VEGF, VEGF receptors/co factor expression by fibroblasts in healthy '\n",
" 'subjects and IPF patients and how they can be r egulated 2)The effect of '\n",
" 'VEGF on normal and fibrotic fibroblast growth and potential for inhibition '\n",
" '3) The effect of a transgenic mouse overexpressing VEGFxxxb in the lung on '\n",
" 'development of Bleomycin induced fibrosis.')\n",
"('Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrotic '\n",
" 'lung disorder with unknown etiology and no effective treatment. The '\n",
" 'expression of the antifibrotic enzyme cyclooxygenase-2 (COX-2) and the '\n",
" 'angiostatic chemokine IP-10 in response to profibrotic cytokines (e.g. '\n",
" 'TGFbeta1 and IL-1beta) is downregulated in IPF, leading to a profibrotic and '\n",
" 'angiogenic environment and contributing to the fibrotic process in IPF. We '\n",
" 'have demonstrated that the downregulation in lung fibroblasts fro m IPF '\n",
" 'patients (F-IPF) is primarily transcriptional due to epigenetic abnormality '\n",
" 'in the form of histone deacetylation. Our preliminary studies also suggest '\n",
" 'that both histone and DNA methylation may play key roles in this '\n",
" 'downregulation. We hypothesise that aberrant histone and DNA methylation is '\n",
" 'responsible for the downregulation of the two genes. We will compare F-IPF '\n",
" 'and fibroblasts from nonfibrotic lung (F-NL) to test the hypothesis. We will '\n",
" 'assess histone and DNA methylation state at the ge ne promoters, explore the '\n",
" 'order of events and the interplay between different epigenetic pathways, '\n",
" 'identify the key molecules that trigger and guide this process, and explore '\n",
" 'the possibility of restoring COX-2 and IP-10 expression. The outcome of the '\n",
" 'studies will improve our understanding of IPF and may prove highly '\n",
" 'beneficial for novel therapeutic strategies.')\n",
"('Pulmonary fibrosis represents the end stage of a heterogeneous group of '\n",
" 'conditions with poor prognosis and no effective treatment. Recent studies '\n",
" 'suggest increased epithelial cell (EC) apoptosis and fibroblast resistance '\n",
" 'to apoptosis contributes to the pathogenesis of fibrosis but the mechanisms '\n",
" 'are incompletely understood. However, the host laboratory has shown that '\n",
" 'patients with idiopathic pulmonary fibrosis (IPF) have a decreased capacity '\n",
" 'to synthesise cyclooxygenase (COX)-2 and prostaglandin E2 (PGE2). COX-2/PGE2 '\n",
" 'induce fibroblast apoptosis and protect epithelial cells from apoptosis but '\n",
" 'their role in regulating apoptosis in fibrotic lung is unknown. I therefore '\n",
" 'hypothesise that the decreased capacity to induce COX-2/PGE2 in patients '\n",
" 'with IPF contributes to pathogenesis by increasing EC apoptosis and '\n",
" 'decreasing fibroblast apoptosis. To address this hypothesis I will determine '\n",
" 'whether COX-2/PGE2 deficiency contributes to human fibrotic lung fibroblast '\n",
" 'resistanceto apoptosis and induction of EC apoptosis in vitro. I will also '\n",
" 'examine the effect of COX-2 deficiency on EC and fibroblast apoptosis in an '\n",
" 'animal model')\n"
]
},
{
"data": {
"text/plain": [
"[None, None, None, None, None, None, None, None, None]"
]
},
"execution_count": 14,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"[pprint.pprint(\"{}\".format(i)) for i in df[df['Description'].str.contains('IPF').fillna(False)]['Description']]"
]
},
{
"cell_type": "code",
"execution_count": 15,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>Financial Year</th>\n",
" <th>Internal ID</th>\n",
" <th>Applicant Surname</th>\n",
" <th>Lead Applicant</th>\n",
" <th>Other Applicant(s)</th>\n",
" <th>Sponsor(s)</th>\n",
" <th>Grant Programme:Title</th>\n",
" <th>Recipient Org:Name</th>\n",
" <th>Region</th>\n",
" <th>Recipient Org:Country</th>\n",
" <th>...</th>\n",
" <th>Planned Dates:Start Date</th>\n",
" <th>Planned Dates:End Date</th>\n",
" <th>Currency</th>\n",
" <th>Amount Awarded</th>\n",
" <th>Award Date</th>\n",
" <th>Approval Committee</th>\n",
" <th>Identifier</th>\n",
" <th>Recipient Org:Identifier</th>\n",
" <th>Funding Org:Name</th>\n",
" <th>Funding Org:Identifier</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>1997</th>\n",
" <td>2016/17</td>\n",
" <td>205949/Z/17/Z</td>\n",
" <td>Byrne</td>\n",
" <td>Dr Adam Byrne</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Seed Award in Science</td>\n",
" <td>Imperial College London</td>\n",
" <td>Greater London</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2017-01-09</td>\n",
" <td>2019-01-09</td>\n",
" <td>GBP</td>\n",
" <td>96063</td>\n",
" <td>2016-11-29</td>\n",
" <td>Science Seeds Advisory Panel</td>\n",
" <td>360G-Wellcome-205949_Z_17_Z</td>\n",
" <td>360G-Wellcome-ORG:Imperial-College-London</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2070</th>\n",
" <td>2016/17</td>\n",
" <td>206234/Z/17/Z</td>\n",
" <td>Bain</td>\n",
" <td>Dr Calum Bain</td>\n",
" <td>NaN</td>\n",
" <td>Prof Moira Whyte</td>\n",
" <td>Sir Henry Dale Fellowship</td>\n",
" <td>University of Edinburgh</td>\n",
" <td>Scotland</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2017-09-01</td>\n",
" <td>2022-09-01</td>\n",
" <td>GBP</td>\n",
" <td>1061297</td>\n",
" <td>2017-02-22</td>\n",
" <td>Sir Henry Dale Fellowship Interview Committee</td>\n",
" <td>360G-Wellcome-206234_Z_17_Z</td>\n",
" <td>360G-Wellcome-ORG:University-of-Edinburgh</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3303</th>\n",
" <td>2015/16</td>\n",
" <td>110086/Z/15/Z</td>\n",
" <td>Mirchandani</td>\n",
" <td>Dr Ananda Mirchandani</td>\n",
" <td>NaN</td>\n",
" <td>Prof Moira Whyte, Prof Sarah Walmsley</td>\n",
" <td>Postdoctoral Training Fellowship for Clinicians</td>\n",
" <td>University of Edinburgh</td>\n",
" <td>Scotland</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2016-03-01</td>\n",
" <td>2019-11-30</td>\n",
" <td>GBP</td>\n",
" <td>325999</td>\n",
" <td>2015-11-19</td>\n",
" <td>Clinical Interview Committee</td>\n",
" <td>360G-Wellcome-110086_Z_15_Z</td>\n",
" <td>360G-Wellcome-ORG:University-of-Edinburgh</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3417</th>\n",
" <td>2015/16</td>\n",
" <td>201291/Z/16/Z</td>\n",
" <td>Reynolds</td>\n",
" <td>Dr Carl Reynolds</td>\n",
" <td>NaN</td>\n",
" <td>Prof Paul Cullinan</td>\n",
" <td>Research Training Fellowship</td>\n",
" <td>Imperial College London</td>\n",
" <td>Greater London</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2016-10-01</td>\n",
" <td>2019-10-01</td>\n",
" <td>GBP</td>\n",
" <td>317313</td>\n",
" <td>2016-03-02</td>\n",
" <td>Public Health and Tropical Medicine Interview ...</td>\n",
" <td>360G-Wellcome-201291_Z_16_Z</td>\n",
" <td>360G-Wellcome-ORG:Imperial-College-London</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4621</th>\n",
" <td>2014/15</td>\n",
" <td>109682/Z/15/Z</td>\n",
" <td>Sinclair</td>\n",
" <td>Prof Ian Sinclair</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Pathfinder Award</td>\n",
" <td>University of Southampton</td>\n",
" <td>South East</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2016-03-01</td>\n",
" <td>2017-11-20</td>\n",
" <td>GBP</td>\n",
" <td>103406</td>\n",
" <td>2015-08-25</td>\n",
" <td>Pathfinders Assessment Group</td>\n",
" <td>360G-Wellcome-109682_Z_15_Z</td>\n",
" <td>360G-Wellcome-ORG:University-of-Southampton</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7619</th>\n",
" <td>2012/13</td>\n",
" <td>100638/Z/12/Z</td>\n",
" <td>Jones</td>\n",
" <td>Dr Mark Jones</td>\n",
" <td>NaN</td>\n",
" <td>Prof Donna Davies</td>\n",
" <td>Research Training Fellowship</td>\n",
" <td>University of Southampton</td>\n",
" <td>South East</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2013-08-01</td>\n",
" <td>2016-07-31</td>\n",
" <td>GBP</td>\n",
" <td>219753</td>\n",
" <td>2013-02-20</td>\n",
" <td>Clinical Interview Committee</td>\n",
" <td>360G-Wellcome-100638_Z_12_Z</td>\n",
" <td>360G-Wellcome-ORG:University-of-Southampton</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9997</th>\n",
" <td>2010/11</td>\n",
" <td>095114/Z/10/Z</td>\n",
" <td>Barratt</td>\n",
" <td>Dr Shaney Barratt</td>\n",
" <td>NaN</td>\n",
" <td>Prof Ann Millar</td>\n",
" <td>Research Training Fellowship</td>\n",
" <td>University of Bristol</td>\n",
" <td>South West</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2011-08-01</td>\n",
" <td>2016-01-31</td>\n",
" <td>GBP</td>\n",
" <td>237389</td>\n",
" <td>2011-03-01</td>\n",
" <td>Clinical Interview Committee</td>\n",
" <td>360G-Wellcome-095114_Z_10_Z</td>\n",
" <td>360G-Wellcome-ORG:University-of-Bristol</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12342</th>\n",
" <td>2008/09</td>\n",
" <td>088751/Z/09/Z</td>\n",
" <td>Pang</td>\n",
" <td>Prof Linhua Pang</td>\n",
" <td>Dr Richard Jenkins, Prof Alan Knox, Dr William...</td>\n",
" <td>NaN</td>\n",
" <td>Project Grant</td>\n",
" <td>University of Nottingham</td>\n",
" <td>East Midlands</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2009-10-01</td>\n",
" <td>2012-09-30</td>\n",
" <td>GBP</td>\n",
" <td>220540</td>\n",
" <td>2009-06-30</td>\n",
" <td>Physiological Sciences Funding Committee</td>\n",
" <td>360G-Wellcome-088751_Z_09_Z</td>\n",
" <td>360G-Wellcome-ORG:University-of-Nottingham</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" <tr>\n",
" <th>16140</th>\n",
" <td>2005/06</td>\n",
" <td>078073/Z/05/Z</td>\n",
" <td>Maher</td>\n",
" <td>Prof Toby Maher</td>\n",
" <td>NaN</td>\n",
" <td>Prof Geoffrey Laurent</td>\n",
" <td>Research Training Fellowship</td>\n",
" <td>University College London</td>\n",
" <td>Greater London</td>\n",
" <td>United Kingdom</td>\n",
" <td>...</td>\n",
" <td>2006-04-01</td>\n",
" <td>2009-05-31</td>\n",
" <td>GBP</td>\n",
" <td>242197</td>\n",
" <td>2005-12-06</td>\n",
" <td>Clinical Interview Committee</td>\n",
" <td>360G-Wellcome-078073_Z_05_Z</td>\n",
" <td>360G-Wellcome-ORG:University-College-London</td>\n",
" <td>The Wellcome Trust</td>\n",
" <td>GB-CHC-210183</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>9 rows × 22 columns</p>\n",
"</div>"
],
"text/plain": [
" Financial Year Internal ID Applicant Surname Lead Applicant \\\n",
"1997 2016/17 205949/Z/17/Z Byrne Dr Adam Byrne \n",
"2070 2016/17 206234/Z/17/Z Bain Dr Calum Bain \n",
"3303 2015/16 110086/Z/15/Z Mirchandani Dr Ananda Mirchandani \n",
"3417 2015/16 201291/Z/16/Z Reynolds Dr Carl Reynolds \n",
"4621 2014/15 109682/Z/15/Z Sinclair Prof Ian Sinclair \n",
"7619 2012/13 100638/Z/12/Z Jones Dr Mark Jones \n",
"9997 2010/11 095114/Z/10/Z Barratt Dr Shaney Barratt \n",
"12342 2008/09 088751/Z/09/Z Pang Prof Linhua Pang \n",
"16140 2005/06 078073/Z/05/Z Maher Prof Toby Maher \n",
"\n",
" Other Applicant(s) \\\n",
"1997 NaN \n",
"2070 NaN \n",
"3303 NaN \n",
"3417 NaN \n",
"4621 NaN \n",
"7619 NaN \n",
"9997 NaN \n",
"12342 Dr Richard Jenkins, Prof Alan Knox, Dr William... \n",
"16140 NaN \n",
"\n",
" Sponsor(s) \\\n",
"1997 NaN \n",
"2070 Prof Moira Whyte \n",
"3303 Prof Moira Whyte, Prof Sarah Walmsley \n",
"3417 Prof Paul Cullinan \n",
"4621 NaN \n",
"7619 Prof Donna Davies \n",
"9997 Prof Ann Millar \n",
"12342 NaN \n",
"16140 Prof Geoffrey Laurent \n",
"\n",
" Grant Programme:Title \\\n",
"1997 Seed Award in Science \n",
"2070 Sir Henry Dale Fellowship \n",
"3303 Postdoctoral Training Fellowship for Clinicians \n",
"3417 Research Training Fellowship \n",
"4621 Pathfinder Award \n",
"7619 Research Training Fellowship \n",
"9997 Research Training Fellowship \n",
"12342 Project Grant \n",
"16140 Research Training Fellowship \n",
"\n",
" Recipient Org:Name Region Recipient Org:Country \\\n",
"1997 Imperial College London Greater London United Kingdom \n",
"2070 University of Edinburgh Scotland United Kingdom \n",
"3303 University of Edinburgh Scotland United Kingdom \n",
"3417 Imperial College London Greater London United Kingdom \n",
"4621 University of Southampton South East United Kingdom \n",
"7619 University of Southampton South East United Kingdom \n",
"9997 University of Bristol South West United Kingdom \n",
"12342 University of Nottingham East Midlands United Kingdom \n",
"16140 University College London Greater London United Kingdom \n",
"\n",
" ... Planned Dates:Start Date Planned Dates:End Date \\\n",
"1997 ... 2017-01-09 2019-01-09 \n",
"2070 ... 2017-09-01 2022-09-01 \n",
"3303 ... 2016-03-01 2019-11-30 \n",
"3417 ... 2016-10-01 2019-10-01 \n",
"4621 ... 2016-03-01 2017-11-20 \n",
"7619 ... 2013-08-01 2016-07-31 \n",
"9997 ... 2011-08-01 2016-01-31 \n",
"12342 ... 2009-10-01 2012-09-30 \n",
"16140 ... 2006-04-01 2009-05-31 \n",
"\n",
" Currency Amount Awarded Award Date \\\n",
"1997 GBP 96063 2016-11-29 \n",
"2070 GBP 1061297 2017-02-22 \n",
"3303 GBP 325999 2015-11-19 \n",
"3417 GBP 317313 2016-03-02 \n",
"4621 GBP 103406 2015-08-25 \n",
"7619 GBP 219753 2013-02-20 \n",
"9997 GBP 237389 2011-03-01 \n",
"12342 GBP 220540 2009-06-30 \n",
"16140 GBP 242197 2005-12-06 \n",
"\n",
" Approval Committee \\\n",
"1997 Science Seeds Advisory Panel \n",
"2070 Sir Henry Dale Fellowship Interview Committee \n",
"3303 Clinical Interview Committee \n",
"3417 Public Health and Tropical Medicine Interview ... \n",
"4621 Pathfinders Assessment Group \n",
"7619 Clinical Interview Committee \n",
"9997 Clinical Interview Committee \n",
"12342 Physiological Sciences Funding Committee \n",
"16140 Clinical Interview Committee \n",
"\n",
" Identifier \\\n",
"1997 360G-Wellcome-205949_Z_17_Z \n",
"2070 360G-Wellcome-206234_Z_17_Z \n",
"3303 360G-Wellcome-110086_Z_15_Z \n",
"3417 360G-Wellcome-201291_Z_16_Z \n",
"4621 360G-Wellcome-109682_Z_15_Z \n",
"7619 360G-Wellcome-100638_Z_12_Z \n",
"9997 360G-Wellcome-095114_Z_10_Z \n",
"12342 360G-Wellcome-088751_Z_09_Z \n",
"16140 360G-Wellcome-078073_Z_05_Z \n",
"\n",
" Recipient Org:Identifier Funding Org:Name \\\n",
"1997 360G-Wellcome-ORG:Imperial-College-London The Wellcome Trust \n",
"2070 360G-Wellcome-ORG:University-of-Edinburgh The Wellcome Trust \n",
"3303 360G-Wellcome-ORG:University-of-Edinburgh The Wellcome Trust \n",
"3417 360G-Wellcome-ORG:Imperial-College-London The Wellcome Trust \n",
"4621 360G-Wellcome-ORG:University-of-Southampton The Wellcome Trust \n",
"7619 360G-Wellcome-ORG:University-of-Southampton The Wellcome Trust \n",
"9997 360G-Wellcome-ORG:University-of-Bristol The Wellcome Trust \n",
"12342 360G-Wellcome-ORG:University-of-Nottingham The Wellcome Trust \n",
"16140 360G-Wellcome-ORG:University-College-London The Wellcome Trust \n",
"\n",
" Funding Org:Identifier \n",
"1997 GB-CHC-210183 \n",
"2070 GB-CHC-210183 \n",
"3303 GB-CHC-210183 \n",
"3417 GB-CHC-210183 \n",
"4621 GB-CHC-210183 \n",
"7619 GB-CHC-210183 \n",
"9997 GB-CHC-210183 \n",
"12342 GB-CHC-210183 \n",
"16140 GB-CHC-210183 \n",
"\n",
"[9 rows x 22 columns]"
]
},
"execution_count": 15,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df[df['Description'].str.contains('IPF').fillna(False)]"
]
},
{
"cell_type": "code",
"execution_count": 33,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"[Text(0,0.5,'Amount Awarded (£)'), Text(0.5,0,'Lead Applicant')]"
]
},
"execution_count": 33,
"metadata": {},
"output_type": "execute_result"
},
{
"data": {
"image/png": "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\n",
"text/plain": [
"<matplotlib.figure.Figure at 0x7ff374cfdd30>"
]
},
"metadata": {},
"output_type": "display_data"
}
],
"source": [
"df1 = df[df['Description'].str.contains('IPF').fillna(False)]\n",
"df1.index = df1['Lead Applicant']\n",
"ax = df1['Amount Awarded'].plot(kind='bar', title='Wellcome funding of IPF research')\n",
"ax.set(xlabel='Lead Applicant', ylabel='Amount Awarded (£)')"
]
}
],
"metadata": {
"kernelspec": {
"display_name": "Python 3",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.5.4"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment